New Launch2 Jan 2025, 06:38 pm
Kwality Pharmaceuticals Secures RCGM Approval for Pre-Clinical Studies of Erythropoietin
AI Summary
Kwality Pharmaceuticals Limited (KPL) has announced that it has secured approval from the Review Committee on Genetic Manipulation (RCGM) to commence pre-clinical toxicity studies for its recombinant Erythropoietin product, 10,000 IU/mL, developed in its Biologics Unit. Erythropoietin is a critical therapeutic used to treat anemia associated with chronic kidney disease (CKD). This approval marks a significant step forward in KPL's commitment to expanding its biologics portfolio and addressing critical healthcare needs. The company is on track to complete the pre-clinical studies and is preparing for the commercialization of the product in the next fiscal.
Key Highlights
- Kwality Pharmaceuticals has secured RCGM approval for pre-clinical studies of Erythropoietin
- The product is a critical therapeutic used to treat anemia associated with chronic kidney disease
- This approval marks a significant step forward in KPL's commitment to expanding its biologics portfolio
- KPL is preparing for the commercialization of the product in the next fiscal
- The pre-clinical toxicity studies for the recombinant Erythropoietin product will be conducted in the Biologics Unit